GlobeNewswire: Galera Therapeutics, Inc. Contains the last 10 of 15 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T19:50:37ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/10/10/1928360/0/en/Galera-Therapeutics-Appoints-Christopher-Degnan-as-Chief-Financial-Officer.html?f=22&fvtc=4&fvtv=43728Galera Therapeutics Appoints Christopher Degnan as Chief Financial Officer2019-10-10T21:02:03Z<![CDATA[MALVERN, Penn., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced Christopher Degnan has been named Chief Financial Officer, effective October 21, 2019.]]>https://www.globenewswire.com/news-release/2019/10/08/1926420/0/en/Galera-Therapeutics-Announces-Two-Year-Tumor-Outcomes-Data-for-GC4419.html?f=22&fvtc=4&fvtv=43728Galera Therapeutics Announces Two-Year Tumor Outcomes Data for GC44192019-10-08T12:00:00Z<![CDATA[Data reinforce potential of GC4419 to become a promising treatment for reducing the incidence of severe oral mucositis in patients with head and neck cancer Data reinforce potential of GC4419 to become a promising treatment for reducing the incidence of severe oral mucositis in patients with head and neck cancer]]>https://www.globenewswire.com/news-release/2019/03/21/1758647/0/en/Galera-Therapeutics-Announces-Presentation-of-Data-from-Phase-2b-Clinical-Trial-of-Avasopasem-Manganese-at-2019-NCCN-Annual-Conference.html?f=22&fvtc=4&fvtv=43728Galera Therapeutics Announces Presentation of Data from Phase 2b Clinical Trial of Avasopasem Manganese at 2019 NCCN Annual Conference2019-03-21T14:07:17Z<![CDATA[Data to be published in the Journal of the National Comprehensive Cancer Network Data to be published in the Journal of the National Comprehensive Cancer Network]]>https://www.globenewswire.com/news-release/2018/10/23/1625924/0/en/Data-from-Galera-Therapeutics-Phase-2b-Clinical-Trial-of-Avasopasem-Manganese-GC4419-Presented-at-ASTRO-Annual-Meeting.html?f=22&fvtc=4&fvtv=43728Data from Galera Therapeutics’ Phase 2b Clinical Trial of Avasopasem Manganese (GC4419) Presented at ASTRO Annual Meeting2018-10-23T21:45:00Z<![CDATA[MALVERN, Penn., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc., a clinical-stage biotechnology company focused on the development of drugs targeting oxygen metabolic pathways with the potential to transform cancer radiotherapy, announced data from its Phase 2b clinical trial evaluating avasopasem manganese (GC4419), a highly selective and potent small molecule dismutase mimetic, in patients with locally advanced squamous cell head and neck cancer were presented today during a scientific session at the American Society for Radiation Oncology Annual Meeting in San Antonio, Tex.]]>https://www.globenewswire.com/news-release/2018/10/16/1621804/0/en/Galera-Therapeutics-Announces-Dosing-of-First-Patient-in-Pivotal-Phase-3-ROMAN-Clinical-Trial-of-Avasopasem-Manganese-GC4419.html?f=22&fvtc=4&fvtv=43728Galera Therapeutics Announces Dosing of First Patient in Pivotal Phase 3 ‘ROMAN’ Clinical Trial of Avasopasem Manganese (GC4419)2018-10-16T11:30:00Z<![CDATA[Data from pivotal trial of avasopasem manganese for the reduction of severe oral mucositis in patients with head and neck cancer intended to support New Drug Application]]>https://www.globenewswire.com/news-release/2018/09/19/1572986/0/en/Galera-Therapeutics-Raises-150-Million-for-GC4419-Phase-3-Trial-and-Pre-Commercialization-Activities-in-Lead-Indication.html?f=22&fvtc=4&fvtv=43728Galera Therapeutics Raises $150 Million for GC4419 Phase 3 Trial and Pre-Commercialization Activities in Lead Indication2018-09-19T11:30:00Z<![CDATA[Pivotal trial of GC4419 for the treatment of severe oral mucositis in patients with head and neck cancer expected to initiate in fourth quarter 2018 Pivotal trial of GC4419 for the treatment of severe oral mucositis in patients with head and neck cancer expected to initiate in fourth quarter 2018]]>https://www.globenewswire.com/news-release/2018/08/20/1553852/0/en/Galera-Therapeutics-Presents-Structure-and-Synthesis-of-GC4419-at-American-Chemical-Society-Annual-Meeting.html?f=22&fvtc=4&fvtv=43728Galera Therapeutics Presents Structure and Synthesis of GC4419 at American Chemical Society Annual Meeting2018-08-20T11:30:00Z<![CDATA[Presentation selected as part of The Halpern Legacy Symposium and press program]]>https://www.globenewswire.com/news-release/2018/06/29/1531721/0/en/Data-from-Galera-Therapeutics-223-Patient-Phase-2b-Clinical-Trial-of-GC4419-Presented-at-MASCC-ISOO-2018-Annual-Meeting.html?f=22&fvtc=4&fvtv=43728Data from Galera Therapeutics’ 223-Patient Phase 2b Clinical Trial of GC4419 Presented at MASCC/ISOO 2018 Annual Meeting2018-06-29T12:10:00Z<![CDATA[GC4419 demonstrated clinically significant reduction in duration and incidence of severe oral mucositis (SOM) in patients with head and neck cancer]]>https://www.globenewswire.com/news-release/2018/06/12/1520242/0/en/Galera-Therapeutics-Announces-Presentation-of-Data-from-Phase-2b-Clinical-Trial-of-GC4419-at-MASCC-ISOO-2018-Annual-Meeting.html?f=22&fvtc=4&fvtv=43728Galera Therapeutics Announces Presentation of Data from Phase 2b Clinical Trial of GC4419 at MASCC/ISOO 2018 Annual Meeting2018-06-12T12:00:00Z<![CDATA[Abstract receives Steven M. Grunberg Memorial Award for excellence in cancer research Abstract receives Steven M. Grunberg Memorial Award for excellence in cancer research]]>https://www.globenewswire.com/news-release/2018/06/03/1515861/0/en/Data-from-223-Patient-Phase-2b-Clinical-Trial-of-Galera-Therapeutics-GC4419-Presented-at-2018-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html?f=22&fvtc=4&fvtv=43728Data from 223-Patient Phase 2b Clinical Trial of Galera Therapeutics’ GC4419 Presented at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting2018-06-03T15:00:00Z<![CDATA[GC4419 met primary endpoint, achieving 92 percent reduction in duration of severe oral mucositis (SOM) in patients with head and neck cancer]]>